INO Shareholder Alert: Inovio Pharmaceuticals Class Action Deadline

Investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) have a deadline of April 7, 2026, to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the company. The lawsuit alleges that Inovio made false and misleading statements regarding its business operations and future prospects, potentially impacting investors who purchased company securities between October 10, 2023, and December 26, 2025.

Allegations of Misleading Statements

The core of the lawsuit centers on claims that Inovio misrepresented information related to the manufacturing of its CELLECTRA device and the anticipated submission of a Biologics License Application (BLA) for its INO-3107 product to the Food and Drug Administration (FDA). Specifically, the complaint alleges that the company did not disclose sufficient information regarding deficiencies in the manufacturing process for the CELLECTRA device. This, in turn, raised concerns about the company’s ability to submit the INO-3107 BLA by the projected timeframe of the second half of 2024.

the lawsuit contends that Inovio lacked adequate data to support claims regarding the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review. These designations can significantly expedite the review process for promising therapies, and the lawsuit suggests that Inovio overstated the likelihood of receiving them. The overall regulatory and commercial outlook for INO-3107 was allegedly misrepresented to investors.

Financial Impact and Investor Losses

The firms investigating the claims – Faruqi & Faruqi, LLP, Glancy Prongay Wolke & Rotter LLP, and Bronstein, Gewirtz & Grossman, LLC – are seeking to represent investors who suffered losses exceeding $50,000 as a result of these alleged misrepresentations. Investors who meet this threshold are encouraged to contact the law firms directly to discuss their legal options.

Faruqi & Faruqi, LLP partner James (Josh) Wilson can be reached at 877-247-4292 or 212-983-9330 (Ext. 1310). Glancy Prongay Wolke & Rotter LLP is also urging investors who purchased Inovio securities during the specified class period to contact them. Bronstein, Gewirtz & Grossman, LLC can be reached at 917-590-0911.

Understanding Biologics License Applications (BLAs)

A Biologics License Application is a request submitted to the FDA for approval to market a biological product. Biological products, such as vaccines and gene therapies, are often more complex to manufacture than traditional pharmaceutical drugs. The BLA process involves a rigorous review of the product’s safety, efficacy, and manufacturing quality. The FDA’s review process can be accelerated through designations like priority review and accelerated approval, which are granted to products that address unmet medical needs or offer significant improvements over existing therapies.

Securities Class Action Lawsuits: A Brief Overview

Securities class action lawsuits are a legal mechanism designed to protect investors who have been harmed by false or misleading statements made by publicly traded companies. These lawsuits typically involve a large group of investors who have collectively suffered financial losses. The process involves identifying a lead plaintiff – an investor who represents the interests of the entire class – and pursuing legal claims against the company and its officers.

If a settlement or judgment is reached in favor of the plaintiffs, investors who purchased the company’s securities during the class period may be eligible to recover some of their losses. The recovery amount is typically determined based on the extent of their individual losses and the overall outcome of the case.

Next Steps for Inovio Investors

Investors who believe they may have been affected by the alleged misrepresentations are advised to review the details of the lawsuit and consult with legal counsel. The deadline to request the role of lead plaintiff is April 7, 2026. A copy of the complaint is available for review, and potential plaintiffs are encouraged to gather documentation related to their Inovio investments, including purchase records and statements.

participation in the lawsuit does not require serving as lead plaintiff. Investors can still potentially benefit from any recovery achieved through the lawsuit even if they do not seek the lead plaintiff role. The firms involved have a history of recovering substantial sums for investors in securities litigation, with Faruqi & Faruqi, LLP reporting hundreds of millions of dollars recovered since its founding in 1995.

This information is for general informational purposes only and should not be considered legal or financial advice. Investors should consult with their own legal and financial advisors to determine the best course of action based on their individual circumstances.